Analytical Data
-
Gene name
MSP-1
- Application
-
Alternative Names
MSP-1；VAP33；Vesicle-associated membrane Protein-associated Protein A
-
Species
E.coli
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P04932
-
Expression Region
937-1260aa
-
AA Sequence
KSSENFYEKILKDSDTFYNESFTNFVKSKADDINSLNDESKRKKLEEDINKLKKTLQLSFDLYNKYKLKLERLFDKKKTVGKYKMQIKKLTLLKEQLESKLNSLNNPKHVLQNFSVFFNKKKEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEESIQTEDNYASLENFKVLSKLEGKLKDNLNLEKKKLSYLSSGLHHLIAELKEVIKNKNYTGNSPSENNTDVNNALESYKKFLPEGTDVATVVSESGSDTLEQSQPKKPASTHVGAESNTITTSQNVDDEVDDVIIVPIFGESEEDYDDLGQVVTGEAVTPSV
-
Molecular Weight
40.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MSP-1 (Merozoite Surface Protein-1) is a critical immunogenic component of the malaria parasite Plasmodium falciparum, which is responsible for the most severe form of malaria. This protein plays a pivotal role in the lifecycle of the parasite, specifically during the invasion of host red blood cells by merozoites— the infectious stage of the parasite. Research on MSP-1 has gained significant attention due to its potential as a candidate for vaccine development aimed at controlling malaria. The protein's ability to elicit strong immune responses makes it a prime target for both vaccine formulation and diagnostic assay development. However, challenges remain in understanding the protein's structure-function relationship and its role in immune evasion. Scientists are exploring various recombinant techniques to produce MSP-1 in sufficient quantities and with appropriate configurations for effective use in clinical trials. Additionally, studies are focusing on identifying the specific immune responses generated against MSP-1 and their correlation with protection against malaria. Advancements in recombinant protein technology, coupled with novel adjuvant strategies, are expected to enhance the efficacy of MSP-1 based vaccines. The ongoing research on MSP-1 contributes to the broader goal of finding effective malaria interventions and could play a significant role in reducing the global burden of this devastating disease.
